Characterization of plasminogen binding to NB4 promyelocytic cells using monoclonal antibodies against receptor-induced binding sites in cell-bound plasminogen

Riferimento: 
J Biomed Biotechnol. 2012;2012:984589.
Autori: 
Jardí M, Fàbregas P, Sagarra-Tió M, Pérez-Lucena MJ, Félez J.
Fonte: 
J Biomed Biotechnol. 2012;2012:984589.
Anno: 
2012
Azione: 
La linea cellulare della leucemia promielocitica (NB4) costituisce un modello unico per esplorare il legame e l'attivazione del plasminogeno sulla superficie delle cellule modulati dal trattamento con l'acido all-trans retinoico.
Target: 
Acido all-trans retinoico/leucemia promielocitica

ABSTRACT
The NB4 promyelocytic cell line exhibits many of the characteristics of acute promyelocytic leukemia blast cells, including the translocation (15 : 17) that fuses the PML gene on chromosome 15 to the RARα gene on chromosome 17. These cells have a very high fibrinolytic capacity. In addition to a high secretion of urokinase, NB4 cells exhibit a 10-fold higher plasminogen binding capacity compared with other leukemic cell lines. When tissue-type plasminogen activator was added to acid-treated cells, plasmin generation was 20-26-fold higher than that generated by U937 cells or peripheral blood neutrophils, respectively. We found that plasminogen bound to these cells can be detected by fluorescence-activated cell sorting using an antiplasminogen monoclonal antibody that specifically reacts with this antigen when it is bound to cell surfaces. All-trans retinoid acid treatment of NB4 cells markedly decreased the binding of this monoclonal antibody. This cell line constitutes a unique model to explore plasminogen binding and activation on cell surfaces that can be modulated by all-trans retinoid acid treatment.
Free PMC Article

Sostanze: